000			01963ngm a2200361 a 4500
001			HST2056_1_2
003			UkLoHST
006			m c
007			cr|cna|||a||||
007			vz|czazum
008			080121s2009 enk|||||||||||s|||v|eng d
028	5	0	_a2056 _bHenry Stewart Talks
035			_a(UkLoHST)1123
035			_a(UkLU-K)000947301
040			_aUkLU-K _beng _cUkLU-K
100	1		_aHirsch, Fred R. _4spk
245	1	0	_aEGFR inhibitors in NSCLC and the role of biomarkers for selection of patients _h[electronic resource] / _cFred R. Hirsch.
260			_aLondon : _bHenry Stewart Talks, _c2009.
300			_a1 online resource (1 streaming video file (36 min.) : _bcolor, sound).
490	1		_aCancer therapy : latest thinking in efficacy and toxicity, _x2056-452X
500			_aAnimated audio-visual presentation with synchronized narration.
500			_aTitle from title frames.
505	0		_aContents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules.
506			_aAccess restricted to subscribers.
538			_aMode of access: World Wide Web.
650		2	_aBiomarkers.
650		2	_aNeoplasms _xcomplications.
650		2	_aNeoplasms _xtherapy.
650		2	_aReceptor, Epidermal Growth Factor _xantagonists & inhibitors.
830		0	_aHenry Stewart talks. _pBiomedical & life sciences collection. _pCancer therapy : latest thinking in efficacy and toxicity.
856	4	0	_uhttps://hstalks.com/bs/1123/
856	4	2	_uhttps://hstalks.com/bs/p/385/ _3Series
999			_c78447 _d78447